CTLA-4-directed Blocking Antibody [EPC]
5 drugs in this class with 199,509 total adverse event reports.
5 Drugs
199,509 Total Reports
114,795 Serious Reports
48,967 Death Reports
| # | Drug Name | Generic Name | Reports | Serious | Deaths |
|---|---|---|---|---|---|
| 1 | Nivolumab | NIVOLUMAB | 94,349 | 55,197 | 24,314 |
| 2 | Ipilimumab | IPILIMUMAB | 42,014 | 22,225 | 9,368 |
| 3 | Trametinib | TRAMETINIB | 23,697 | 12,388 | 5,097 |
| 4 | Dabrafenib | DABRAFENIB | 20,691 | 10,115 | 4,365 |
| 5 | Durvalumab | DURVALUMAB | 18,758 | 14,870 | 5,823 |